Does treating hyperlipidaemia with medication prevent complications?

Helen Colhoun

    Research output: Chapter in Book/Report/Conference proceedingChapter


    There is now good evidence supporting the efficacy and safety of currently available drugs for lowering low-density lipoprotein cholesterol (LDL-C) in the prevention of cardiovascular disease (CVD) in patients with diabetes, particularly with statin therapy. Almost all patients with type 2 diabetes who can tolerate the medication warrant such therapy. The extent to which lowering triglycerides and raising HDL-C with currently available drugs reduces CVD risk remains less clear. Trials of fibrates in patients with diabetes and established CVD have given conflicting results. In patients without CVD, lowering LDL-C with a statin seems more efficacious than focusing on triglycerides and HDL-C with a fibrate. The effect of sole therapy with niacin on CVD risk in diabetes is untested. Trials are under way to provide an evidence base for some important outstanding questions, in particular the role of combination therapy (statin plus fibrate, statin plus niacin, statin plus ezetimibe) in patients at goal for LDL-C and the efficacy of lipid lowering in advanced renal disease
    Original languageEnglish
    Title of host publicationThe Evidence Base for Diabetes Care
    EditorsWilliam H. Herman, Ann Louise Kinmonth, Nicholas J. Wareham, Rhys Williams
    Place of PublicationLondon
    ISBN (Electronic)9780470682807
    ISBN (Print)9780470032749
    Publication statusPublished - 2010


    Dive into the research topics of 'Does treating hyperlipidaemia with medication prevent complications?'. Together they form a unique fingerprint.

    Cite this